Literature DB >> 17400176

A transmembrane osteoclastic protein-tyrosine phosphatase regulates osteoclast activity in part by promoting osteoclast survival through c-Src-dependent activation of NFkappaB and JNK2.

Mehran Amoui1, Matilda H-C Sheng, Shin-Tai Chen, David J Baylink, K-H William Lau.   

Abstract

This study evaluated the effects of overexpression of wild-type (WT) or phosphatase-deficient (PD) mutant of an osteoclastic protein-tyrosine phosphatase (PTP-oc) in RAW/C4 cells. Osteoclast-like cells derived from WT-PTP-oc overexpressing clones increased, while those derived from PD-PTP-oc expressing clones decreased, their resorption activity. WT-PTP-oc clones had lower apoptosis, lower caspase 3/7 activity, reduced c-Src tyr-527 phosphorylation (PY527) and IkappaBalpha cellular levels, and increased NFkappaB activation and JNK phosphorylation. Overexpression of PD-PTP-oc or PTP-oc siRNA treatment increased apoptosis, caspase 3/7 activity, PY527 and IkappaBalpha levels, and decreased NFkappaB and JNK2 activation. Inhibition of the c-Src kinase blocked the PTP-oc-mediated NFkappaB and JNK2 activation. Blocking the NFkappaB activation had no effect on the JNK2 activation. Inhibiting the NFkappaB and/or JNK2 pathway prevented the PTP-oc-mediated reduction in apoptosis. In conclusion, PTP-oc activates osteoclast activity in part by promoting osteoclast survival through the PTP-oc-mediated c-Src-dependent activation of NFkappaB and JNK2.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17400176     DOI: 10.1016/j.abb.2007.02.025

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  11 in total

1.  Conditional Disruption of miR17~92 in Osteoclasts Led to Activation of Osteoclasts and Loss of Trabecular Bone In Part Through Suppression of the miR17-Mediated Downregulation of Protein-Tyrosine Phosphatase-oc in Mice.

Authors:  Kin-Hing William Lau; Virginia M Stiffel; Charles H Rundle; Mehran Amoui; Jordan Tapia; Tyler D White; Matilda H-C Sheng
Journal:  JBMR Plus       Date:  2017-08-01

2.  Protein tyrosine phosphatase epsilon regulates integrin-mediated podosome stability in osteoclasts by activating Src.

Authors:  Shira Granot-Attas; Chen Luxenburg; Eynat Finkelshtein; Ari Elson
Journal:  Mol Biol Cell       Date:  2009-08-19       Impact factor: 4.138

Review 3.  RNA therapeutics targeting osteoclast-mediated excessive bone resorption.

Authors:  Yuwei Wang; David W Grainger
Journal:  Adv Drug Deliv Rev       Date:  2011-09-10       Impact factor: 15.470

Review 4.  A novel miR17/protein tyrosine phosphatase-oc/EphA4 regulatory axis of osteoclast activity.

Authors:  Kin-Hing William Lau; Matilda H-C Sheng
Journal:  Arch Biochem Biophys       Date:  2018-05-17       Impact factor: 4.013

5.  Lyn kinase and ZAP70 are substrates of PTPROt in B-cells: Lyn inactivation by PTPROt sensitizes leukemia cells to VEGF-R inhibitor pazopanib.

Authors:  Tasneem Motiwala; Jharna Datta; Huban Kutay; Satavisha Roy; Samson T Jacob
Journal:  J Cell Biochem       Date:  2010-07-01       Impact factor: 4.429

6.  Targeted transgenic expression of an osteoclastic transmembrane protein-tyrosine phosphatase in cells of osteoclastic lineage increases bone resorption and bone loss in male young adult mice.

Authors:  Matilda H-C Sheng; Mehran Amoui; Virginia Stiffel; Apurva K Srivastava; Jon E Wergedal; K-H William Lau
Journal:  J Biol Chem       Date:  2009-02-25       Impact factor: 5.157

7.  Role of protein-tyrosine phosphatases in regulation of osteoclastic activity.

Authors:  M H-C Sheng; K-H W Lau
Journal:  Cell Mol Life Sci       Date:  2009-06       Impact factor: 9.207

8.  Protein tyrosine phosphatases ε and α perform nonredundant roles in osteoclasts.

Authors:  Eynat Finkelshtein; Sutada Lotinun; Einat Levy-Apter; Esther Arman; Jeroen den Hertog; Roland Baron; Ari Elson
Journal:  Mol Biol Cell       Date:  2014-04-02       Impact factor: 4.138

9.  Maternal embryonic leucine zipper kinase inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease.

Authors:  Joséphine Muller; Arnold Bolomsky; Sophie Dubois; Elodie Duray; Kathrin Stangelberger; Erwan Plougonven; Margaux Lejeune; Angélique Léonard; Caroline Marty; Ute Hempel; Frédéric Baron; Yves Beguin; Martine Cohen-Solal; Heinz Ludwig; Roy Heusschen; Jo Caers
Journal:  Haematologica       Date:  2018-05-10       Impact factor: 9.941

10.  PTPRA facilitates cancer growth and migration via the TNF-α-mediated PTPRA-NF-κB pathway in MCF-7 breast cancer cells.

Authors:  Canfeng Lin; Shubo Xin; Xiaoguang Huang; Feiran Zhang
Journal:  Oncol Lett       Date:  2020-08-20       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.